Galcanezumab Effects on Migraine Severity and Symptoms in Japanese Patients with Episodic Migraine: Secondary Analysis of a Phase 2 Randomized Trial

INTRODUCTION: Galcanezumab, a humanized monoclonal antibody against calcitonin gene-related peptide, is a preventive migraine treatment. In global, randomized, placebo-controlled trials, galcanezumab reduced migraine headache severity and the frequency of migraine headaches associated with nausea an...

Descripción completa

Detalles Bibliográficos
Autores principales: Igarashi, Hisaka, Shibata, Mamoru, Ozeki, Akichika, Matsumura, Taka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9837349/
https://www.ncbi.nlm.nih.gov/pubmed/36266558
http://dx.doi.org/10.1007/s40120-022-00410-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9837349/
https://www.ncbi.nlm.nih.gov/pubmed/36266558
http://dx.doi.org/10.1007/s40120-022-00410-3

Ejemplares similares